Innovent Biologics Inc.
IVBXF | OTC
$9.90
-$1.40 (-12.39%)
At close: Oct 30, 2026, 2:35 PM ET
$9.90
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 4:00 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q4 2025 Dec 31, 2025 | Q2 2025 Jun 30, 2025 | Q4 2024 Dec 31, 2024 | Q2 2024 Jun 30, 2024 | Q4 2023 Dec 31, 2023 | Q2 2023 Jun 30, 2023 | Q4 2022 Dec 31, 2022 | Q2 2022 Jun 30, 2022 | Q4 2021 Dec 31, 2021 | Q2 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 8.5B | 7.09B | 5.95B | 5.47B | 3.95B | 3.5B | 2.7B | 2.32B | 2.24B | 2.33B | 1.94B |
Cost of Revenue | 1.28B | 1.69B | 1.39B | 1.32B | 1.09B | 1.03B | 781.76M | 673.38M | 708.38M | 667.74M | 556.68M |
Gross Profit | 7.22B | 5.4B | 4.57B | 4.15B | 2.86B | 2.48B | 1.92B | 1.64B | 1.53B | 1.66B | 1.39B |
Operating Income | 1.88B | -8.41M | 742.04M | -15.19M | -740.69M | -960.46M | -718.85M | -1.67B | -1.45B | -1.72B | -981.35M |
Interest Income | 351.34M | n/a | 129.11M | 393.83M | n/a | 402.55M | 50.29M | 132.41M | n/a | 142.8M | n/a |
Pretax Income | 1.59B | -58.19M | 897.12M | 313.96M | -392.59M | -888.3M | -256.11M | -1.17B | -998.91M | -1.64B | -1B |
Net Income | 1.24B | -20.76M | 834.32M | 297.99M | -392.62M | -888.76M | -139.15M | -1.23B | -950.47M | -1.73B | -1B |
Selling & General & Admin | 3.68B | 3.82B | 2.82B | 2.89B | 2.2B | 2.14B | 1.72B | 1.62B | 1.81B | 2.03B | 1.39B |
Research & Development | 1.66B | 1.62B | 1.01B | 1.28B | 1.4B | 1.3B | 922.82M | 1.7B | 1.17B | 1.35B | 974.32M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 5.34B | 5.44B | 3.83B | 4.17B | 3.6B | 3.44B | 2.13B | 2.95B | 2.49B | 3.41B | 2.36B |
Interest Expense | 40.36M | 18.03M | n/a | n/a | n/a | n/a | n/a | n/a | 44.57M | 112.51M | 27.1M |
Selling & Marketing Expenses | n/a | 3.34B | 2.38B | 2.47B | 1.88B | 1.75B | 1.35B | 1.19B | 1.4B | 1.54B | 1.08B |
Cost & Expenses | 6.62B | 7.13B | 5.21B | 5.48B | 4.69B | 4.46B | 2.91B | 3.62B | 3.19B | 4.08B | 2.92B |
Income Tax Expense | 353.57M | -37.44M | 62.8M | 15.98M | 35K | 462K | -116.96M | 57.25M | -48.44M | 86.89M | 152K |
Shares Outstanding (Basic) | 1.73B | 1.71B | 1.69B | 1.63B | 1.62B | 1.58B | 1.54B | 1.52B | 1.46B | 1.45B | 1.45B |
Shares Outstanding (Diluted) | 1.8B | 1.79B | 1.69B | 1.63B | 1.62B | 1.58B | 1.54B | 1.52B | 1.47B | 1.46B | 1.45B |
EPS (Basic) | 0.72 | -0.01 | 0.49 | 0.18 | -0.24 | -0.56 | -0.09 | -0.82 | -0.64 | -1.18 | -0.70 |
EPS (Diluted) | 0.68 | -0.01 | 0.49 | 0.18 | -0.24 | -0.56 | -0.09 | -0.82 | -0.64 | -1.18 | -0.70 |
EBITDA | 2.21B | 417.84M | 892.31M | -231.41M | -248.86M | -741.75M | -546.59M | -1.53B | -1.34B | -1.63B | -903.65M |
EBIT | 1.88B | -8.41M | 742.04M | -323.55M | -432.32M | -845.1M | -718.85M | -1.67B | -1.45B | -1.72B | -981.35M |
Depreciation & Amortization | 327.09M | 426.25M | 150.28M | 92.14M | 183.46M | 103.34M | 172.25M | 139.89M | 105.2M | 87.7M | 77.7M |
Add to Watchlist
Select watchlists to add or remove IVBXF